Activin E, body fat distribution, and insulin resistance: human genetics, liver–adipose communication, and translational perspectives
Frontiers in Endocrinology · 17.11.2026 · 17
DOI: 10.3389/fendo.2026.2005408 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Endocrinology, online erschienen am 17.11.2026. Verfasst von Zhuoshi Yang und 2 weiteren Autor:innen. Die Arbeit nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Insulin resistance (IR) contributes to type 2 diabetes (T2DM), metabolic dysfunction-associated steatotic liver disease and cardiovascular disease. Human genetics and preclinical studies link the hepatokine activin E, encoded by INHBE, and its type I receptor ALK7 to body-fat distribution, adipose lipolysis and metabolic control. Large exome-sequencing studies associate heterozygous INHBE predicted loss-of-function (pLOF) variants with lower body mass index-adjusted waist-to-hip ratio; one multi-ancestry study also reported more favorable metabolic traits and approximately 28% lower odds of T2DM. ACVR1C coding variants show similar associations, although ALK7 receives input from several ligands. Hepatocytes upregulate INHBE during non-esterified fatty-acid load and cellular stress. In mouse and adipocyte systems, secreted activin E signals through adipocyte ALK7 complexes containing ActRIIA or ActRIIB, activates SMAD2/3, and suppresses PPARγ-dependent lipolytic programs and β3-adrenergic signaling. This feedback preserves lipid stores during fasting but may promote adipocyte hypertrophy and catecholamine resistance in obesity. Lower activin E-ALK7 signaling is associated with more favorable fat distribution in human genetics, whereas reduced fat mass in mouse loss-of-function models can coexist with hepatic lipid accumulation and impaired insulin action. In one constitutive high-fat-fed mouse model, complete Inhbe loss increased hepatic lipid burden and produced a lean MASH-like phenotype. Durable efficacy and long-term hepatic safety require clinical validation. This review examines activin E biology, human genetics and preclinical evidence at three intervention levels: the activin E ligand, the ALK7 receptor and shared type II receptors, with particular attention to hepatic safety.
Zitieren
APA
Yang, Z., Zhao, N., & Ma, J. (2026). Activin E, body fat distribution, and insulin resistance: human genetics, liver–adipose communication, and translational perspectives. Frontiers in Endocrinology, 17. https://doi.org/10.3389/fendo.2026.2005408
Vancouver
Yang Z, Zhao N, Ma J. Activin E, body fat distribution, and insulin resistance: human genetics, liver–adipose communication, and translational perspectives. Frontiers in Endocrinology. 2026;17. doi:10.3389/fendo.2026.2005408
BibTeX
@article{Yang2026,
author = {Yang, Zhuoshi and Zhao, Na and Ma, Jian},
title = {Activin E, body fat distribution, and insulin resistance: human genetics, liver–adipose communication, and translational perspectives},
journal = {Frontiers in Endocrinology},
year = {2026},
volume = {17},
doi = {10.3389/fendo.2026.2005408}
}
EUVIMED